The development of a physiologically based pharmacokinetic model for the whole body in which inhalation, exhalation, and metabolism in respiratory tract tissues are taken into account is described. As an example of the model's use, the results of several experiments in which rats and humans were exposed to styrene were simulated; these results are discussed. The predicted results agree with the empirical data and with the modeling results of others.
Get full access to this article
View all access options for this article.
References
1.
MillerF. J., OvertonJ. H.Jr., JaskotR. H., MenzelD. B.A model of the regional uptake of gaseous pollutants in the lung. I. The sensitivity of the uptake of ozone in the human lung to lower respiratory track secretions and exercise. Toxicol. Appl. Pharmacol. 1985;79:11–27
2.
RamseyJ. C., AndersenM. E.A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. Toxicol. Appl. Pharmacol. 1984;73:159–175
3.
WeibelE. R.Morphometry of the Human Lung. New York: Academic Press, Inc.; 1963, pp. 136–140.
4.
WilkinsonG. R.Prediction of in vivo parameters of drug metabolism and distribution from in vitro studies. Pp. 80-95 in Pharmacokinetics in Risk Assessment: Drinking Water and Health. Washington, D.C: National Academy Press; 1987, pp. 80–95.
